Home Cart Sign in  
Chemical Structure| 848942-61-0 Chemical Structure| 848942-61-0

Structure of Sapitinib
CAS No.: 848942-61-0

Chemical Structure| 848942-61-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD8931 is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively.

Synonyms: AZD8931; AZD-8931

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sapitinib

CAS No. :848942-61-0
Formula : C23H25ClFN5O3
M.W : 473.93
SMILES Code : O=C(NC)CN1CCC(OC2=CC3=C(NC4=CC=CC(Cl)=C4F)N=CN=C3C=C2OC)CC1
Synonyms :
AZD8931; AZD-8931
MDL No. :MFCD18385011
InChI Key :DFJSJLGUIXFDJP-UHFFFAOYSA-N
Pubchem ID :11488320

Safety of Sapitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Sapitinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR, IC50:4 nM

  • ErbB3

    ErbB3, IC50:4 nM

  • HER2/ErbB2

    ErbB2, IC50:3 nM

  • HER2

    ErbB2, IC50:3 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MPNST cells 1, 5, 10 µmol/L 7 days To evaluate the effect of Sapitinib on the proliferation of MPNST cells, the results showed that Sapitinib significantly reduced the number of cells in all four MPNST cell lines. PMC10477957
HCP-1 2 μM 72 hours To assess the effect of HER3 inhibitor AZD8931 on CRC cell viability PMC6318043
HT29 2 μM 72 hours To assess the effect of HER3 inhibitor AZD8931 on CRC cell viability PMC6318043
SW480 2 μM 72 hours To assess the effect of HER3 inhibitor AZD8931 on CRC cell viability PMC6318043
U-CH1 1 μM 96 hours To evaluate the growth inhibitory effect of Sapitinib on chordoma cells, results showed significant growth inhibition in U-CH1 cells PMC4922416
U-CH2 1 μM 96 hours To evaluate the growth inhibitory effect of Sapitinib on chordoma cells, results showed no significant growth inhibition in U-CH2 cells PMC4922416
MUG-Chor1 1 μM 96 hours To evaluate the growth inhibitory effect of Sapitinib on chordoma cells, results showed significant growth inhibition in MUG-Chor1 cells PMC4922416
SUM149 cells 0.01, 0.1, 1, 2 μmol/L 72 hours AZD8931 significantly suppressed the proliferation of SUM149 cells in a dose-dependent manner. PMC4061513
FC-IBC-02 cells 0.01, 0.1, 1, 2 μmol/L 72 hours AZD8931 significantly suppressed the proliferation of FC-IBC-02 cells in a dose-dependent manner. PMC4061513
SUM149 cells 1 μmol/L 48 and 72 hours AZD8931 significantly induced apoptosis in SUM149 cells. PMC4061513
FC-IBC-02 cells 1 μmol/L 48 and 72 hours AZD8931 significantly induced apoptosis in FC-IBC-02 cells. PMC4061513
BT474c 0.03-3 µmol/l 5 days To evaluate the effect of AZD5363 and AZD8931 combination treatment on cell growth, results showed synergistic growth inhibition in HER2-amplified cell lines. PMC4501645
SKBR3 0.03-3 µmol/l 5 days To evaluate the effect of AZD5363 and AZD8931 combination treatment on cell growth, results showed synergistic growth inhibition in HER2-amplified cell lines. PMC4501645
HCC1954 0.03-3 µmol/l 5 days To evaluate the effect of AZD5363 and AZD8931 combination treatment on cell growth, results showed synergistic growth inhibition in HER2-amplified cell lines. PMC4501645
KPL4 0.03-3 µmol/l 5 days To evaluate the effect of AZD5363 and AZD8931 combination treatment on cell growth, results showed synergistic growth inhibition in HER2-amplified cell lines. PMC4501645
SKOV3 cells 584 nM Sapitinib showed weaker growth inhibition in SKOV3 cells with an IC50 value of 584 nM. PMC5063458
ES2 cells >10 µM Sapitinib showed poor growth inhibition in ES2 cells with an IC50 value greater than 10 µM. PMC5063458
Cov318 cells >10 µM Sapitinib showed poor growth inhibition in Cov318 cells with an IC50 value greater than 10 µM. PMC5063458
Ovcar-3 cells >10 µM Sapitinib showed poor growth inhibition in Ovcar-3 cells with an IC50 value greater than 10 µM. PMC5063458
L-JIMT-1 cells 0.1, 1, 10, 50, 100, 500, 1000, 10000 nMol/L 5 days To evaluate the growth inhibitory effect of Sapitinib on L-JIMT-1 cells, results showed that L-JIMT-1 cells were insensitive to Sapitinib, IC50 was not reached. PMC10973002
JIMT-1 cells 0.1, 1, 10, 50, 100, 500, 1000, 10000 nMol/L 5 days To evaluate the growth inhibitory effect of Sapitinib on JIMT-1 cells, results showed that JIMT-1 cells were insensitive to Sapitinib, IC50 was not reached. PMC10973002
human liver microsomes 10 μM 2 hours To test the generation of reactive intermediates from SAP in human liver microsomes and identify its metabolites and reactive intermediates. PMC9073192

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Subcutaneous xenograft model Oral 3 mg/kg body weight To evaluate the inhibitory effect of HER3 inhibitor AZD8931 on CRC tumor growth PMC6318043
C.B-17 SCID mice IBC xenograft model Oral gavage 28 ± 6 mg/kg daily Once daily for 2 to 4 weeks AZD8931 monotherapy significantly suppressed tumor growth in IBC xenograft models, and the combination with paclitaxel was more effective than monotherapy. PMC4061513
mice HCC1954 xenograft model oral 25 mg/kg Once daily, until the end of the experiment To evaluate the anti-tumour activity of AZD5363 and AZD8931 combination treatment in HER2-amplified breast cancer models, results showed that the combination treatment was more effective than monotherapy, leading to significant tumour regression. PMC4501645

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00637039 Advanced Solid Malignancies PHASE1 COMPLETED 2025-12-12 Research Site, Berlin, Germany... More >>|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation Less <<
NCT00879346 Healthy PHASE1 COMPLETED 2025-07-09 Research Site, Alderley Park, ... More >>Cheshire, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.55mL

2.11mL

1.06mL

21.10mL

4.22mL

2.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories